Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 20406818 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Nistal-Villán E, et al. (2010) Negative role of RIG-I serine 8 phosphorylation in the regulation of interferon-beta production. J Biol Chem 285, 20252-61 20406818
Download Sites

S8-p - DDX58 (human)
Orthologous residues
DDX58 (human): S8‑p, DDX58 (mouse): , DDX58 (duck): S8‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, mass spectrometry, mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  lung cancer
 Relevant cell lines - cell types - tissues:  293T (epithelial), A459, HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
calyculin A increase
IFN-beta decrease
virus infection decrease
Downstream Regulation
 Effect of modification (function):  intracellular localization, molecular association, regulation, ubiquitination
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
TRIM25 (human) Disrupts co-immunoprecipitation
MAVS (human) Disrupts co-immunoprecipitation


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.